Latest news with #IRB
Yahoo
3 hours ago
- Business
- Yahoo
Establishment Labs to Present at Jefferies Global Healthcare Conference
NEW YORK, June 03, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Sign in to access your portfolio
Business Wire
3 hours ago
- Business
- Business Wire
Establishment Labs to Present at Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at
Yahoo
3 hours ago
- Business
- Yahoo
Establishment Labs to Present at Jefferies Global Healthcare Conference
NEW YORK, June 03, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@
New Straits Times
a day ago
- Business
- New Straits Times
Expert advice on how SMEs can avoid tax filling as once-a-year scramble
KUALA LUMPUR: Small and medium enterprises (SMEs) should take a more structured approach to manage their corporate tax obligations to avoid penalties and ensure smooth compliance. Chartered Tax Institute of Malaysia (CTIM) council member Harvindar Singh said while many business owners remain focused on day-to-day operations, tax matters often take a back seat until submission deadlines loom, resulting in rushed filings and avoidable mistakes. "Tax filing should not be a once-a-year scramble. With the right approach and record-keeping, SMEs can make it a smoother, more predictable process," Harvindar told Business Times in an interview. Companies have eight months from the end of their financial year to submit their income tax return (Form C), factoring in the Inland Revenue Board's (IRB) one-month grace period. For instance, a company with a Dec 31, 2024 year-end must file by Aug 31, 2025. More crucially, companies must also submit tax estimates (Form CP204) a month before the new financial year and make monthly installments starting from the second month. These estimates can be revised in the sixth, ninth and 11th months of the basis year. "The IRB discourages taxpayers from using the government as a funding mechanism. It's a pay-as-you-earn system," Harvindar said, adding that penalties apply for underestimation or late payments. Common mistakes and missed opportunities Among the most common errors SMEs make are misclassifying deductible and non-deductible expenses, overstating capital expenditures as tax-deductible, and failing to maximise claims on capital allowances. "A lot of taxpayers do not analyse their expenses properly. Renovation costs, for example, may be lumped under repairs and maintenance and mistakenly claimed as deductions," he explained. Harvindar emphasised the importance of being aware of eligibility criteria and maintaining proper documentation when it comes to tax incentives. He said some incentives, like pioneer status or reinvestment allowances, must be approved in advance and may be rejected if a business has already started operations. "Documentation is key. The IRB can request for original or digital records, and if these are missing or incomplete, legitimate claims may be rejected," he said. He also advised businesses to structure employee compensation wisely and consider incentives such as the Private Retirement Scheme, which offers corporate tax deductions of up to seven per cent on contributions. Be audit-ready, always Harvindar pointed out that companies must always be audit-ready as part of Malaysia's self-assessment tax regime. Tax audits are typically announced in advance, but investigations can occur unannounced, especially if the IRB suspects malpractice. "Keep your records for at least seven years, as required by law. Sales invoices, purchase receipts, payroll records, loan agreements—these are all vital," he said. Businesses with related party transactions must ensure proper transfer pricing documentation is in place to avoid scrutiny during audits. Staying ahead of tax law changes With rapid tax law developments, including the rollout of e-invoicing and capital gains tax, Harvindar encouraged SMEs to stay updated through tax professionals. "Even as a consultant, it's overwhelming to keep up. It's critical for SMEs to work closely with their tax agents or accountants to stay compliant and avoid costly oversights," he said. Ultimately, good tax planning, according to Harvindar, is not about avoiding tax, but aligning business decisions with the law for optimum outcomes.
The Sun
2 days ago
- Business
- The Sun
Tax Matters – Should contracts related to employment be stamped?
THERE is significant discussion in the media and in various publications on whether contracts related to employment should be stamped. This has arisen because the Inland Revenue Board (IRB) has recently been visiting taxpayers and advising them that their contracts of employment and other documents relating to employment should be stamped, and late stamping penalties will be applicable. The visits to taxpayers were conducted under the new Stamp Duty Audit Framework issued on Jan 1, 2025. To add weight to the current treatment, the Malaysian Industrial, Commercial and Service Employers Association (Micsea) has issued a statement mentioning that it has agreed with the IRB a concession that the penalty will be waived for all employment contracts stamped on or before Dec 31, 2025. The self-assessment system for stamp duty purposes will only be applicable from Jan 1, 2026, which allows the IRB to conduct audits and make additional assessments for any shortfalls for up to five years after the duty is paid or would have been paid. As to whether the IRB can go back prior to Jan 1, 2026 (i.e. before the self-assessment kicks in) is debatable. The normal understanding is: You should not apply the law retrospectively; and secondly the issue of whether the IRB has the right to impose stamp duty will only be confined to instruments which are mandatorily required to be stamped. At the moment, the assessment of stamp duty is on an official system where the taxpayer sends the document for adjudication and seeks an assessment. Although there is an audit framework applicable from Jan 1, 2025 which allows the IRB to visit taxpayers, the findings from the audit cannot invoke additional taxes unless there is a mandatory requirement in the legislation for the instruments to be stamped. There is significant discussion and publications by learned parties who have expressed the view that all written instruments must be stamped. The justification for their position is not clear as there is difficulty in finding the necessary legislation to support their position. When it comes to employment contracts, Micsea states in its publication that employment contract, letter of transfer (where it will be perceived as a new employment) and fixed term contracts (including each contract issued after the expiration date) should be stamped. Promotion and bonus letters, annual increment letters, letter of transfer within the company which does not amount to a new employment and secondment letters which do not amount to a new employment contract are 'exempted' from stamping. This appears to be their understanding with the IRB. All the above written documents are 'instruments' as defined under Section 2 of the Stamp Act 1949. Where is the authority to dissect the above instruments between subject to stamping or exempted from stamping? This position does not seem to resonate with the law. There is no specific provision in the Stamp Act 1949 that states that employment contracts are required to be stamped other than the fact that employment contract is an 'instrument' under the Stamp Act 1949. Based on this analysis, up to Dec 31, 2025, before the self-assessment system kicks in, there does not seem to be a need to stamp employment contracts and contracts related to employment. To allow businesses to carry on without this ambiguity, it will be best if the visits by the IRB are clearly done with the intention of educating and preparing taxpayers for 2026 to get them ready for the self-assessment system. In such visits, taxpayers should have the benefit of our esteemed IRB officials who will be up-to-date technically and knowledgeable on the workings of the stamp duty system to help taxpayers comply with their responsibilities.
